This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Best-Performing Obesity Drug Stock May Surprise You

OREX Chart OREX data by YCharts

LA JOLLA, Calif. ( TheStreet) -- Orexigen Therapeutics (OREX - Get Report) won't have a weight-loss pill approved and ready for sale until well into 2014 but its stock is generating far greater returns this year than rivals Arena Pharmaceuticals (ARNA - Get Report) and Vivus (VVUS - Get Report) with drugs already on the market.

Shares of Orexigen are up 12% this year, which makes it the only obesity drug stock making money for investors. Vivus shares are down 8% while Arena has lost 22% of its value.

Vivus botched the commercial launch of its Qsymia weight-loss pill and is now fighting off a dissident shareholder, First Manhattan, which wants to replace the company's board of directors and management team. For Arena, the first few weeks of prescription data reported for the early Belviq launch have done nothing to shake investors' perception that its drug is ineffectual.

Orexigen is still conducting a large cardiovascular safety study of its obesity pill Contrave, with an interim analysis and results expected in the third quarter. If Contrave gets a passing grade from the study, the drug will be resubmitted to the FDA by the end of the year or in early 2014, the company has said.

Anticipation for the Contrave heart-safety study results is one explanation for the outperformance of Orexigen shares this year, but so is the company's relatively low valuation compared to Arena and Vivus.

At the start of the year, Orexigen's market value of $488 million was dwarfed by Arena ($2.1 billion market cap) and Vivus ($1.5 billion market cap.)

Through the first half of the year, the valuation gap between the three companies has narrrowed somewhat. OREX Market Cap Chart OREX Market Cap data by YCharts

Contrave is a pill combining two already-approved medicines -- bupropion and naltrexone. Efficacy-wise, Contrave demonstrated greater weight loss than Arena's Belviq but less than Vivus' Qsymia.

Being the third obesity pill to launch commercially may be seen as a disadvantage, but of all three companies, Orexigen has the best, most experienced marketing partner in Takeda. The diabetes drug Actos is a blockbuster product for Takeda, which will leverage that metabolic drug marketing expertise when Contrave hits the market.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.62 0.00%
OREX $0.46 0.00%
VVUS $1.50 0.00%
AAPL $95.18 0.00%
FB $117.43 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs